Banking giant Goldman Sachs (NYSE: GS) has identified several stocks that are expected to trend higher in the future based on their key fundamentals.
In particular, the bank’s support is a significant step that can influence investors’ decisions and the performance of certain stocks. In this context, Finbold has identified two stocks highlighted by Goldman Sachs that can potentially turn a modest investment of $100 into $1000 by 2025.
Alphabet (NASDAQ:GOOGL)
Alphabet (NASDAQ: GOOGL), the parent company of Google, continues to be a driving force in the technology industry. Goldman Sachs predicts a strong growth trajectory for Alphabet, fueled by its diversified portfolio and strategic investments.
The company’s core business – search engine YouTube, cloud computing services and projects such as Waymo (self-driving cars) and Verily (healthcare) – are crucial to its long-term success.
According to Goldman Sachs, Alphabet’s financial health, its innovative product pipeline and its investments in artificial intelligence (AI) and cloud technology are key factors that could lead to a significant increase in the stock’s value. In addition, Alphabet’s continued efforts to improve its advertising capabilities and expand its cloud services are likely to contribute significantly to its revenue.
With these factors in mind, there is potential for Alphabet stock to appreciate significantly, with a $100 investment reaching a much higher value by 2025. However, the exact return may vary.
By the close of trading on August 16, GOOGL was trading at $163, up nearly 1% on the day. The stock was volatile over the week, gaining 0.1%.
Eli Lilly (NYSE: LLY)
Eli Lilly (NYSE: LLY) has become a leader in the pharmaceutical industry, particularly with its advances in treating diabetes and obesity. The company’s stock has seen significant gains due to its strong product pipeline and the recent FDA approval of Zepbound (tirzepatide), a drug used to treat chronic obesity.
This new drug is expected to compete with Novo Nordisk’s Wegovy because it offers a price advantage and better weight loss results.
Goldman Sachs analysts highlighted Eli Lilly’s innovative approach and successful clinical trials that have cemented its position in the market. The company’s strategic focus on developing treatments with high market potential and its robust research and development capabilities underscore its growth prospects.
In addition, Eli Lilly’s stock has received numerous buy recommendations from analysts, with price targets suggesting significant upside potential. The company’s diversified portfolio and continued expansion into new therapeutic areas support its long-term growth prospects.
Because of these strengths, Eli Lilly stock also has significant growth potential, meaning that a $100 investment could potentially turn into a much larger sum by 2025.
At press time, LLY was trading at $920, down 1% on the day. However, the stock is up over 1.3% on the week.
While no investment is guaranteed, Alphabet and Eli Lilly have high growth potential. For investors looking for promising opportunities through 2025, these stocks may be worth considering, as they can turn a modest investment into significantly greater value.
Disclaimer: The content of this website does not constitute investment advice. Investments are speculative. When you invest, your capital is at risk.
